Fierce Biotech March 24, 2023
By James Waldron

Graf Acquisition Corp. IV is just the latest in a string of blank-check companies serial special purpose acquisition company founder James Graf has set up. (Andrii Yalanskyi/Getty Images)

After a number of high-profile special purpose acquisition company announcements toward the end of last year, these deals once again dropped off in 2023. But that doesn’t mean the low-key revival of this reverse merger model has died.

Case in point is NKGen Biotech, a natural killer (NK) cell therapy-focused company, which announced plans to go public via a merger with blank-check company Graf Acquisition Corp. IV. Santa Ana, California-based NKGen was set up in 2017 with a focus on neurodegenerative diseases and oncology and is now led by Paul...

Today's Sponsors

Upfront Healthcare

Today's Sponsor


Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Top 25 healthcare companies: Fortune 500
Epistemic AI launches biomedical GPT at BIO
Embracing Generative AI: Why Its Disruption is Positive for Pharma
Taking Stock Of US Healthcare And Its Leadership Dilemma
Getting Cancer Drugs To The Right Patients At The Right Time

Share This Article